相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Aaron C. Tan et al.
LUNG CANCER (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Community-driven development of a modified progression-free survival ratio for precision oncology
Andreas Mock et al.
ESMO OPEN (2019)
The evidence framework for precision cancer medicine
Jeffrey A. Moscow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
Katharina Schwarze et al.
GENETICS IN MEDICINE (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions
Kathryn A. Phillips et al.
VALUE IN HEALTH (2018)
The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial
Arnaud Pages et al.
GENETICS IN MEDICINE (2017)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loic Verlingue et al.
EUROPEAN JOURNAL OF CANCER (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
The influence of subclonal resistance mutations on targeted cancer therapy
Michael W. Schmitt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing
Kirsten J. M. van Ninnwegen et al.
CLINICAL CHEMISTRY (2016)
Limits to Personalized Cancer Medicine
Ian F. Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Precision Medicine - Personalized, Problematic, and Promising
J. Larry Jameson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecularly targeted cancer therapy: some lessons from the past decade
Min Huang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
B. A. M. Heemskerk-Gerritsen et al.
ANNALS OF ONCOLOGY (2013)
分享论文
